Cargando…

An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection

BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanco, Natalia, Foxman, Betsy, Malani, Anurag N., Zhang, Min, Walk, Seth, Rickard, Alexander H., Eisenberg, Marisa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553947/
https://www.ncbi.nlm.nih.gov/pubmed/28800598
http://dx.doi.org/10.1371/journal.pone.0182815
_version_ 1783256703934922752
author Blanco, Natalia
Foxman, Betsy
Malani, Anurag N.
Zhang, Min
Walk, Seth
Rickard, Alexander H.
Eisenberg, Marisa C.
author_facet Blanco, Natalia
Foxman, Betsy
Malani, Anurag N.
Zhang, Min
Walk, Seth
Rickard, Alexander H.
Eisenberg, Marisa C.
author_sort Blanco, Natalia
collection PubMed
description BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence and effectiveness of treatment of recurring CDI remains unclear. We aim to assess the role of sporulation/germination patterns on risk of recurrence, and the relative effectiveness of the recommended tapered/pulsing regimens using an in silico model. METHODS: We created a compartmental in-host mathematical model of CDI, composed of vegetative cells, toxins, and spores, to explore whether sporulation and germination have an impact on recurrence rates. We also simulated the effectiveness of three tapered/pulsed vancomycin regimens by ribotype. RESULTS: Simulations underscored the importance of sporulation/germination patterns in determining pathogenicity and transmission. All recommended regimens for recurring CDI tested were effective in reducing risk of an additional recurrence. Most modified regimens were still effective even after reducing the duration or dosage of vancomycin. However, the effectiveness of treatment varied by ribotype. CONCLUSION: Current CDI vancomycin regimen for treating recurrent cases should be studied further to better balance associated risks and benefits.
format Online
Article
Text
id pubmed-5553947
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55539472017-08-25 An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection Blanco, Natalia Foxman, Betsy Malani, Anurag N. Zhang, Min Walk, Seth Rickard, Alexander H. Eisenberg, Marisa C. PLoS One Research Article BACKGROUND: Clostridium difficile infection (CDI) is a significant nosocomial infection worldwide, that recurs in as many as 35% of infections. Risk of CDI recurrence varies by ribotype, which also vary in sporulation and germination rates. Whether sporulation/germination mediate risk of recurrence and effectiveness of treatment of recurring CDI remains unclear. We aim to assess the role of sporulation/germination patterns on risk of recurrence, and the relative effectiveness of the recommended tapered/pulsing regimens using an in silico model. METHODS: We created a compartmental in-host mathematical model of CDI, composed of vegetative cells, toxins, and spores, to explore whether sporulation and germination have an impact on recurrence rates. We also simulated the effectiveness of three tapered/pulsed vancomycin regimens by ribotype. RESULTS: Simulations underscored the importance of sporulation/germination patterns in determining pathogenicity and transmission. All recommended regimens for recurring CDI tested were effective in reducing risk of an additional recurrence. Most modified regimens were still effective even after reducing the duration or dosage of vancomycin. However, the effectiveness of treatment varied by ribotype. CONCLUSION: Current CDI vancomycin regimen for treating recurrent cases should be studied further to better balance associated risks and benefits. Public Library of Science 2017-08-11 /pmc/articles/PMC5553947/ /pubmed/28800598 http://dx.doi.org/10.1371/journal.pone.0182815 Text en © 2017 Blanco et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Blanco, Natalia
Foxman, Betsy
Malani, Anurag N.
Zhang, Min
Walk, Seth
Rickard, Alexander H.
Eisenberg, Marisa C.
An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title_full An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title_fullStr An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title_full_unstemmed An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title_short An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection
title_sort in silico evaluation of treatment regimens for recurrent clostridium difficile infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553947/
https://www.ncbi.nlm.nih.gov/pubmed/28800598
http://dx.doi.org/10.1371/journal.pone.0182815
work_keys_str_mv AT blanconatalia aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT foxmanbetsy aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT malanianuragn aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT zhangmin aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT walkseth aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT rickardalexanderh aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT eisenbergmarisac aninsilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT blanconatalia insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT foxmanbetsy insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT malanianuragn insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT zhangmin insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT walkseth insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT rickardalexanderh insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection
AT eisenbergmarisac insilicoevaluationoftreatmentregimensforrecurrentclostridiumdifficileinfection